Paris-based biotech company Primaa, which develops AI for automated cancer diagnostics, has raised €7 million in funding from the partnership fund between MH Innov’ and Elaia, and SWEN Capital Partners.
- Established in 2018 by Fanny Sockeel, Stéphane Sockeel, and Marie Sockeel, Primaa develops AI software for automated and precise cancer diagnostics. The company’s platform uses deep learning and image analysis to identify and quantify cancer biomarkers on histological slides.
- Its tools, including Cleo Breast and Cleo Skin, analyze tissue samples to detect breast and skin cancers, supporting pathologists by reducing manual counting and improving diagnostic consistency.
- The AI models are trained on large datasets of annotated slides, enabling the software to recognize patterns associated with malignancies and provide quantitative outputs that inform clinical decisions.
- Primaa is also expanding its technology to cervical and prostate cancer, with ongoing development aimed at predictive modeling for disease progression and relapse risk.
As well as saving time and improving accuracy in diagnostics, our tools make life much easier for practitioners. The automatic counting and detection features completely relieve them of certain time-consuming tasks," explains Fanny Sockeel, CEO and co-founder of Primaa.
Details of the deal
- The investors are MH Innov’ and Elaia’s partnership fund, SWEN Capital Partners, Super Capital, and members of the Wendel family.
- Primaa plans to use the funding to expand its sales and support, accelerate AI feature development, and pursue international growth, including FDA certification in the US.
